Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2017, specifically dated January 20, 2017. The report details a registered direct offering of American Depositary Shares (ADSs) entered into on January 18, 2017, with certain institutional investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5,000,000 from the sale of 2,500,000 ADSs at $2.00 per share.
- Warrants Issued: Investors received unregistered warrants to purchase 1,250,000 ADSs (50% of the offering size).
- Warrant Terms: Exercise price of $2.25 per ADS; exercisable after six months for a period of five and a half years.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a cash fee of 6% of the aggregate purchase price plus a $50,000 expense allowance.
- Agent Warrants: The placement agent received compensation warrants equal to 5% of the aggregate number of ADSs sold.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, or debt figures.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of 2,500,000 new ADSs and the creation of 1,250,000 warrant shares. The transaction represents a significant capital raise intended to fund operations, though specific allocation of funds is not detailed in this text.
Outlook, Risks, and Contingencies
- Closing Contingency: The offering is expected to close on or about January 24, 2017, subject to customary closing conditions. Failure to satisfy these conditions may prevent the closing.
- Forward-Looking Statements: The company warns that statements regarding the closing date and future expectations are not guaranteed and may not occur due to factors beyond its control.
- Regulatory Status: Warrants and underlying ADSs are sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D exemptions. They are not registered and cannot be resold in the U.S. without an effective registration statement or applicable exemption.
Investor Verification Checklist
- Verify the actual closing date of the offering, as the January 24, 2017 date is subject to conditions.
- Review the full Securities Purchase Agreement (Exhibit 10.2) for specific representations, warranties, and indemnification provisions.
- Confirm the total dilution impact including the 5% placement agent warrants.
- Check subsequent filings for the use of proceeds and any updates to the company's liquidity position.
- Note that the press release date mentioned in the text (December 19, 2017) appears to be a typographical error in the source document, as the filing is dated January 2017; verify the actual announcement date.